New Results
An infectivity-enhancing site on the SARS-CoV-2 spike protein is targeted by COVID-19 patient antibodies
Yafei Liu, Wai Tuck Soh, Asa Tada, Akemi Arakawa, Sumiko Matsuoka, Emi E. Nakayama, Songling Li, Chikako Ono, Shiho Torii, Kazuki Kishida, Hui Jin, Wataru Nakai, Noriko Arase, Atsushi Nakagawa, Yasuhiro Shindo, Masako Kohyama, Hironori Nakagami, Keisuke Tomii, Koichiro Ohmura, Shiro Ohshima, Masato Okada, View ORCID ProfileYoshiharu Matsuura, Daron M. Standley, Tatsuo Shioda, View ORCID ProfileHisashi Arase
doi: https://doi.org/10.1101/2020.12.18.423358
Yafei Liu
1Department of Immunochemistry, Research Institute for Microbial Diseases, Osaka University, Osaka, Japan
2Laboratory of Immunochemistry, World Premier International Immunology Frontier Research Centre, Osaka University, Osaka, Japan
Wai Tuck Soh
2Laboratory of Immunochemistry, World Premier International Immunology Frontier Research Centre, Osaka University, Osaka, Japan
Asa Tada
2Laboratory of Immunochemistry, World Premier International Immunology Frontier Research Centre, Osaka University, Osaka, Japan
Akemi Arakawa
2Laboratory of Immunochemistry, World Premier International Immunology Frontier Research Centre, Osaka University, Osaka, Japan
Sumiko Matsuoka
1Department of Immunochemistry, Research Institute for Microbial Diseases, Osaka University, Osaka, Japan
Emi E. Nakayama
3Department of Viral Infections, Research Institute for Microbial Diseases, Osaka University, Osaka, Japan
Songling Li
4Dept. Genome Informatics, Research Institute for Microbial Diseases, Osaka University, Osaka, Japan
Chikako Ono
5Department of Molecular Virology, Research Institute for Microbial Diseases, Osaka University, Osaka, Japan
Shiho Torii
5Department of Molecular Virology, Research Institute for Microbial Diseases, Osaka University, Osaka, Japan
Kazuki Kishida
2Laboratory of Immunochemistry, World Premier International Immunology Frontier Research Centre, Osaka University, Osaka, Japan
Hui Jin
1Department of Immunochemistry, Research Institute for Microbial Diseases, Osaka University, Osaka, Japan
Wataru Nakai
1Department of Immunochemistry, Research Institute for Microbial Diseases, Osaka University, Osaka, Japan
2Laboratory of Immunochemistry, World Premier International Immunology Frontier Research Centre, Osaka University, Osaka, Japan
Noriko Arase
6Department of Dermatology, Graduate school of Medicine, Osaka University, Osaka, Japan
Atsushi Nakagawa
7Department of Respiratory Medicine, Kobe City Medical Center General Hospital, Hyogo, Japan
Yasuhiro Shindo
8Drug Discovery Research Center, HuLA immune Inc., Osaka, Japan
Masako Kohyama
1Department of Immunochemistry, Research Institute for Microbial Diseases, Osaka University, Osaka, Japan
2Laboratory of Immunochemistry, World Premier International Immunology Frontier Research Centre, Osaka University, Osaka, Japan
Hironori Nakagami
9Department of Health Development and Medicine, Graduate school of Medicine, Osaka University, Osaka, Japan
Keisuke Tomii
7Department of Respiratory Medicine, Kobe City Medical Center General Hospital, Hyogo, Japan
Koichiro Ohmura
10Department of Rheumatology, Kobe City Medical Center General Hospital, Hyogo, Japan
Shiro Ohshima
11Department of Clinical Research, Osaka Minami Medical Center, Kawachinagano, Osaka, Japan
Masato Okada
12Department Oncogene Research, Research Institute for Microbial Diseases, Osaka University, Osaka, Japan
Yoshiharu Matsuura
5Department of Molecular Virology, Research Institute for Microbial Diseases, Osaka University, Osaka, Japan
Daron M. Standley
4Dept. Genome Informatics, Research Institute for Microbial Diseases, Osaka University, Osaka, Japan
Tatsuo Shioda
3Department of Viral Infections, Research Institute for Microbial Diseases, Osaka University, Osaka, Japan
Hisashi Arase
1Department of Immunochemistry, Research Institute for Microbial Diseases, Osaka University, Osaka, Japan
2Laboratory of Immunochemistry, World Premier International Immunology Frontier Research Centre, Osaka University, Osaka, Japan
Article usage
Posted December 18, 2020.
An infectivity-enhancing site on the SARS-CoV-2 spike protein is targeted by COVID-19 patient antibodies
Yafei Liu, Wai Tuck Soh, Asa Tada, Akemi Arakawa, Sumiko Matsuoka, Emi E. Nakayama, Songling Li, Chikako Ono, Shiho Torii, Kazuki Kishida, Hui Jin, Wataru Nakai, Noriko Arase, Atsushi Nakagawa, Yasuhiro Shindo, Masako Kohyama, Hironori Nakagami, Keisuke Tomii, Koichiro Ohmura, Shiro Ohshima, Masato Okada, Yoshiharu Matsuura, Daron M. Standley, Tatsuo Shioda, Hisashi Arase
bioRxiv 2020.12.18.423358; doi: https://doi.org/10.1101/2020.12.18.423358
An infectivity-enhancing site on the SARS-CoV-2 spike protein is targeted by COVID-19 patient antibodies
Yafei Liu, Wai Tuck Soh, Asa Tada, Akemi Arakawa, Sumiko Matsuoka, Emi E. Nakayama, Songling Li, Chikako Ono, Shiho Torii, Kazuki Kishida, Hui Jin, Wataru Nakai, Noriko Arase, Atsushi Nakagawa, Yasuhiro Shindo, Masako Kohyama, Hironori Nakagami, Keisuke Tomii, Koichiro Ohmura, Shiro Ohshima, Masato Okada, Yoshiharu Matsuura, Daron M. Standley, Tatsuo Shioda, Hisashi Arase
bioRxiv 2020.12.18.423358; doi: https://doi.org/10.1101/2020.12.18.423358
Subject Area
Subject Areas
- Biochemistry (11753)
- Bioengineering (8752)
- Bioinformatics (29201)
- Biophysics (14974)
- Cancer Biology (12100)
- Cell Biology (17413)
- Clinical Trials (138)
- Developmental Biology (9422)
- Ecology (14182)
- Epidemiology (2067)
- Evolutionary Biology (18309)
- Genetics (12245)
- Genomics (16804)
- Immunology (11869)
- Microbiology (28098)
- Molecular Biology (11596)
- Neuroscience (60975)
- Paleontology (451)
- Pathology (1871)
- Pharmacology and Toxicology (3238)
- Physiology (4959)
- Plant Biology (10427)
- Synthetic Biology (2886)
- Systems Biology (7340)
- Zoology (1651)